SARMACEUTICALS LGD4033 Ligandrol

Overview: LGD-4033, also known as Ligandrol, is a potent selective androgen receptor modulator (SARM) that binds to androgen receptors with high affinity and selectivity. Its primary mechanism involves activating androgen receptors in muscle and bone tissue while minimizing effects on other organs. Compared to other SARMs, LGD-4033 demonstrates a particularly high binding affinity to androgen receptors, with a Ki value of approximately 1 nM. This exceptional affinity contributes to its potent anabolic effects at relatively low doses. Additionally, LGD-4033 exhibits a more favorable anabolic-to-androgenic ratio than many other SARMs, potentially offering greater muscle-building effects with reduced androgenic side effects.
 
Benefits:
Enhanced Muscle Growth: Promotes lean muscle mass development and strength gains more effectively than many other SARMs.
Improved Body Composition: Facilitates fat loss while preserving muscle tissue.
Accelerated Recovery: Contributes to reduced recovery times post-exercise.
Bone Density Support: May support bone health by enhancing bone mineral density.
Potential Therapeutic Applications: Demonstrates promise in treating muscle wasting conditions and osteoporosis.
 
Dosage and Usage: 30mL bottle, 20mg/ml.
 Standard dosing for research purposes ranges from 5-10 mg per day. Administration is typically recommended once daily due to its long half-life of 24-36 hours. Common research cycles last between 8-12 weeks.
 
Ingredients: LGD-4033 (Ligandrol) Solvents (DMSO, Propylene Glycol, Vegetable Glycerin) USP Grade
 
Additional Information: LGD-4033 is produced under stringent quality control standards, ensuring high purity and consistency. Each batch undergoes rigorous analytical testing to verify its composition and efficacy.
 
Disclaimer: This product is intended solely for laboratory research use only. Not for human consumption. Not for human or veterinary diagnostic or therapeutic use. Users should consult relevant literature and adhere to appropriate protocols. Not suitable for non-research use or by individuals under 18 years of age.